Zevra Therapeutics Stock Discussion

🚨 This Week’s PDUFA:
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...

$Zevra Therapeutics (ZVRA.US)$ Not sure yet? But its looking like it sure wants to try!

$MGO Global (MGOL.US)$ $Dermata Therapeutics (DRMA.US)$ $Zevra Therapeutics (ZVRA.US)$ $Sangamo Therapeutics (SGMO.US)$ $Shimmick (SHIM.US)$
📊⚡️📊

$Zevra Therapeutics (ZVRA.US)$ Monday sure boom !!!

$Zevra Therapeutics (ZVRA.US)$ Finally a ticker with FDA news that actually moves! Hehehe. Halt came off after close so Monday could be good as well? NFA

$Zevra Therapeutics (ZVRA.US)$
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Zevra Therapeutics said a Food and Drug Administration advisory committee voted favorably on Arimoclomol as a treatment for patients with Niemann-Pick Disease Type C.
The FDA Genetic Metabolic Diseases Advisory Committee voted 11-5 that data support Arimoclomol as effective in the treatment of patients with the rare progre...

$Zevra Therapeutics (ZVRA.US)$
Zevra Therapeutics Inc: Arimoclomol Nda Has Been Assigned a Prescription Drug User Fee Act Action Date of Sept 21, 2024